HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

(2020) Sarah Fidler et al.   LANCET

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

(2019) Felicity Hartnell et al.   Frontiers in Immunology

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells

(2019) Alba Ruiz et al.   Frontiers in Immunology

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

(2019) Boris Julg et al.   Lancet HIV

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

(2019) Ravindra K. Gupta et al.   NATURE

Impact of treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who had initiated antiretroviral therapy during the early phase of infection

(2019) Erin D Huiting et al.   JOURNAL OF INFECTIOUS DISEASES

Structural topology defines protective CD8+ T cell epitopes in the HIV proteome

(2019) Gaurav D. Gaiha et al.   SCIENCE

Targeting the Latent Reservoir for HIV-1

(2018) Srona Sengupta et al.   IMMUNITY

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

(2018) Donn J. Colby et al.   NATURE MEDICINE

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1

(2018) Nicola J. Borthwick et al.   PLoS One

The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies

(2018) Golnaz Namazi et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals

(2018) Sara Moron-Lopez et al.   AIDS

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

(2017) Michael C. Sneller et al.   Science Translational Medicine

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects

(2017) Gemma Hancock et al.   Journal of the International AIDS Society

Eradication of HIV-1 latent reservoirs through therapeutic vaccination

(2017) Joshua Pankrac et al.   AIDS Research and Therapy

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

(2017) Sara Morón-López et al.   PLoS One

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

(2016)   AIDS

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy

(2016) Steffen Leth et al.   AIDS

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection

(2016) Beatrice Ondondo et al.   MOLECULAR THERAPY

Defective proviruses rapidly accumulate during acute HIV-1 infection

(2016) Katherine M Bruner et al.   NATURE MEDICINE

Lessons from acute HIV infection

(2016) Merlin L. Robb et al.   Current Opinion in HIV and AIDS

Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine

(2016) James Theiler et al.   Scientific Reports

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial

(2016) Steffen Leth et al.   Lancet HIV

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

(2016) Gaudensia Mutua et al.   Molecular Therapy-Methods & Clinical Development

Progress Towards an HIV Cure: Update from the 2014 International AIDS Society Symposium

(2015) Jenny Louise Anderson et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

(2015) Beatriz Mothe et al.   Journal of Translational Medicine

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

(2015) Kai Deng et al.   NATURE

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

(2014) Ai Kawana-Tachikawa et al.   PLoS One

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

(2014) Emma-Jo Hayton et al.   PLoS One

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

(2014) Richard Brad Jones et al.   PLoS Pathogens

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

(2014) Datsen George Wei et al.   PLoS Pathogens

HIV-1 DNA predicts disease progression and post-treatment virological control

(2014) James P Williams et al.   eLife

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells

(2013) Liang Shan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

(2013) Nicola Borthwick et al.   MOLECULAR THERAPY

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study

(2013) Thomas Harrer et al.   VACCINE

Comparison of HDAC inhibitors in clinical development

(2013) Thomas Aagaard Rasmussen et al.   Human Vaccines & Immunotherapeutics

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

(2013) Asier Sáez-Cirión et al.   PLoS Pathogens

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein

(2010) Robert T. Schooley et al.   JOURNAL OF INFECTIOUS DISEASES

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

(2009) Brigitte Autran et al.   AIDS

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

(2009) S. Woo et al.   CLINICAL CANCER RESEARCH